Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Neoplasms 3Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Glioma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphoid 1Gliosarcoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1

Interventions

mogamulizumab 4denileukin diftitox 4Vorinostat 4Panobinostat 4zanolimumab 3cobomarsen 3Brentuximab Vedotin 3Bexarotene 3tenalisib 2selinexor 2marizomib 2hypericin 2Vitamin B 12 2Rituximab 2Folic Acid 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2tislelizumab 1tinostamustine 1sapacitabine 1romidepsin 1resminostat 1quisinostat 1ontuxizumab 1navitoclax 1forodesine 1fludarabine phosphate 1enzastaurin 1belinostat 1abexinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Cutaneous × enzastaurin × Clear all
NCT00744991 2020-10-19

A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

Eli Lilly and Company

Phase 2 Completed
25 enrolled 14 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡